Updates in HR+ HER2- Advanced or Metastatic Breast Cancer

A discussion on how to apply updated data from ESMO 2021 to treatment decisions for patients with HR+/HER2- advanced breast cancer.

EP. 1: Identifying PIK3CA Mutations in HR+ HER2- MBC

October 11th 2021

Kicking off a discussion regarding recent data presented at ESMO 2021, a panel of breast oncologists share their preferences for conducting molecular testing to identify mutations such as PIK3CA that can help determine how to treat patients with HR+/HER2- metastatic breast cancer.

EP. 2: HR+ MBC: Prognostic Factors and Treatment Planning

October 11th 2021

Dr. Neil Iyengar highlights variables that factor into treatment decisions for patients with HR+/HER2- metastatic breast cancer.

EP. 3: Frontline Treatment Approaches for HR+/HER2- MBC

October 18th 2021

A panel of breast oncologists review first-line treatment options for patients with HR+/HER2- metastatic breast cancer, commenting on treatment advances utilizing CKD4/6 inhibitors.

EP. 4: HR+/HER2- MBC: Updated OS Data From MONALEESA-2

October 18th 2021

Reactions to new overall survival results from the MONALEESA-2 study in patients with HR+/HER2- advanced breast cancer in the first-line setting.

EP. 5: Ribociclib + ET for HR+/HER2- MBC: QoL and OS Data

October 25th 2021

Considerations regarding the association of quality of life with overall survival in patients with HR+/HER2- advanced breast cancer treated with ribociclib and endocrine therapy.

EP. 6: MONALEESA Data in HR+/HER2- MBC: Sequencing Therapy

October 25th 2021

Insight on how to best sequence therapy for patients with HR+/HER2- advanced breast cancer based on updated data from the MONALEESA trials.

EP. 7: HR+/HER2- MBC: CDK4/6 Inhibitors + ET as Frontline Therapy

November 1st 2021

Dr. Sarah Sammons highlights various first-line treatment approaches that combine CDK4/6 inhibitors with endocrine therapy as treatment for HR+/HER2- metastatic breast cancer.

EP. 8: HR+/HER2- MBC: CKD4/6 Inhibitor Treatment Toxicities

November 1st 2021

Clinical pearls regarding best practices preventing and/or managing common treatment-related adverse events associated with CDK4/6 inhibitors used to treat HR+/HER2- metastatic breast cancer.

EP. 9: Comparison of CDK4/6 Therapies for HR+/HER2- MBC

November 8th 2021

Similarities and differences between available CDK4/6 inhibitors used to treat HR+/HER2- metastatic breast cancer.

EP. 10: CDK4/6 Treatment Selection for HR+/HER2- MBC

November 8th 2021

The impact of recent data presented at ESMO 2021 in terms of selecting an appropriate CDK4/6 inhibitor as first-line treatment of HR+/HER2- metastatic breast cancer.

EP. 11: Targeting the PI3K Pathway in HR+/HER2- MBC

November 15th 2021

The rationale for investigating the role of therapies that target the PI3K pathway in HR+/HER2- metastatic breast cancer.

EP. 12: PI3K Inhibitors for PIK3CA-Mutated HR+ MBC

November 15th 2021

Considerations for treating patients with HR+/HER2- metastatic breast cancer with alpelisib, a PI3K inhibitor, following frontline treatment with a CDK4/6 inhibitor.

EP. 13: Managing Patients With HR+ MBC on PI3K Therapy

November 22nd 2021

Breast oncologists share pearls regarding best practices treating patients with HR+/HER2- metastatic breast cancer with PI3K inhibitor therapy and mitigating treatment-related adverse events.

EP. 14: PI3K Therapy for HR+/HER2- MBC: Metabolic Syndrome

November 22nd 2021

Strategies to help breast oncologists counsel patients on metabolic conditions when treating patients with HR+/HER2- metastatic breast cancer with PI3K inhibitors.

EP. 15: Sequencing Therapy in HR+/HER2- MBC

November 29th 2021

Variables that impact how breast oncologists should sequence therapies when managing patients with HR+/HER2- metastatic breast cancer.

EP. 16: Novel Agents Under Study for HR+/HER2- MBC

November 29th 2021

A panel of breast oncologists highlight exciting treatment strategies being explored in clinical trials to help address treatment limitations in HR+/HER2- metastatic breast cancer.

EP. 17: Treatment Advances in HR+/HER2- MBC

November 29th 2021

Final takeaways from a discussion on best practices treating HR+/HER2- metastatic breast cancer with CDK4/6 inhibitors and PI3K therapies based on data presented at ESMO 2021.